ClinicalTrials.gg
CompletedNCT04997785Updated Jan 18, 2023

PENG Block for Traumatic Hip Fracture in the Emergency Department

An interventional study of Ultrasound-guided Pericapsular Nerve Group (PENG) Block in Hip Fractures, Acute Pain and Emergency Department, sponsored by Dalin Tzu Chi General Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-01-18.

Sponsored by Dalin Tzu Chi General Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

The study is a multicenter single-blinded randomized comparative trial. Adult patients older than 20 years of age presenting with acute hip fracture in emergency department between January 1st, 2021 and December 31st, 2021 will be enrolled. (NOTE: The study was paused temporarily due to local SARS-2 COVID-19 virus pandemic restrictions. Finally, we conducted the study from August 30th, 2021 to May 08th, 2022.) Included patients will receive analgesia with either pericapsular nerve group (PENG) block or intravenous morphine. The primary outcome measure was pain scores (Numeric Rating Scale (NRS) 0 to 10) at rest and with movement. Secondary outcomes were rescue opioids use, complications, length of hospital stay, and patient-reported outcomes.

Read the detailed description

Study design and setting This is multicenter, randomized controlled comparative trial conducted at Far Eastern Memorial Hospital and Dalin Tzu Chi Hospital, which are academic, level 1 trauma centers in Taiwan. The investigators plan to conduct the study from January 1st to May 8th, 2022. It will be paused temporarily if local coronavirus disease 2019 (COVID-19) virus pandemic restrictions. The trial is registering on ClinicalTrials.gov number. The study was reviewed and approved by the Institutional Review Board. The study conforms to the Consolidated Standards of Reporting Trials (CONSORT) and the CONSORT extension for trials reporting patient- related outcomes.

Selection of participants Patients aged >=20 years presenting to the emergency department (ED) with a diagnosis of traumatic hip fracture from January 1st to May 8th, 2022 will be included. The investigators exclude patients who are aged \<20 years, have coagulopathy, injection site infection, allergy to opioids or local anesthetics, initial pulse oximetry measures of oxygen saturation \<92%, initial systolic blood pressure \< 90 mmHg, chronic opioid use, non-communicative, experiences major trauma, fractures happened > 24 hours, and request conservative(non-operative) treatments. The investigators also exclude patients if the nerve block (NB) providers are unavailable. Written informed consent is acquired from all participants.

Randomization procedures and rationale All the included patients are randomized to either PENG block or intravenous morphine. Because PENG block is a novel technique for regional hip analgesia, well-trained emergency physicians are not available every day. Randomizing patients at the point of ED visit was considered impractical. Therefore, the investigators randomize each visit week before the study begins, and well-trained PENG block providers will be arranged on duty in the weeks randomized for PENG block. The unit of randomization will be the weeks, using random number generation in Microsoft Excel by a statistician who is not involved in the trial.

Study intervention PENG blocks is performed by Emergency Medicine board-certified emergency physicians (EPs) with standard training program. PENG block is performed using a spinal needle (BD® 20G × 90 mm) at the level of of anterior superior iliac spine, parallel to the inguinal crease, with real-time ultrasound guidance, according to the steps published by Girón-Arango et al in 2018. The investigators used 20 ml of 1% lidocaine for nerve block because this drug has a short onset time, which is adequate to relieve pain before surgical intervention. Regimens of regional anesthesia with a longer duration of action are not preferred in our department because delayed onset of regional anesthesia particularly impedes orthopedic assessment in EDs. Dosage of intravenous morphine was determined according to 0.1 mg per kg; EPs were instructed to aim to reduce the pain by 50% or per patient request. They were encouraged to wait for at least 15 minutes after the study procedure before administering additional analgesia.

Outcome measures Primary outcome was postdose NRS pain score at rest and with movement. The NRS for pain with movement was assessed by lifting the affected leg. The examiner assessed NRS score with movement by gently raising the patient's affected limb about 15 degree by flexing the hip with the knee in extension. NRS score was assessed as part of standard care at various timepoints, including at baseline, immediately after the analgesic treatment, at 10, 30, 60, and 120 minutes postdose time points, every 2 h thereafter until discharge from the ED, and at the time of discharge from the ED and arrival at the orthopedic ward before surgery.

Secondary outcomes were postdose quadriceps strength, rescue opiate use, complications, length of ED stay, length of hospital stay, and patient-reported outcomes.

Quadriceps strength was assessed using the knee extension test and Oxford muscle strength scale. Rescue opioid consumption was measured in morphine milligram equivalents (MME) administered over all ED visits during the study timeframe. Any complications or side effects of nerve blocks, including local infection, intravascular injection of local anesthetics and immediate systemic toxicity, will be recorded. In opioid group, any side effects of opioids such as drowsiness, desaturation, nausea and vomiting, delirium, or respiratory distress, will be recorded. Patient-reported outcome defined as patient satisfaction (120 minutes after initial analgesics, patients were asked whether they would choose the same anesthetic handling; "yes" or "no").

Sample size calculation and statistical analyses Sample size could not be calculated, as there is no prior trial on comparison of PENG block and intravenous morphine in patient with hip fractures. This trial will be a pilot trial. Hence, the investigators intend to recruit 200 participants in total using a 1:1 allocation ratio, with 100 participants randomised into each arm. Chi-squared test or Fisher's exact test was used for categorical variables, and Student's t-test was used for continuous variable. Logistic regression was used to analyze data with dichotomous outcomes; p \< 0.05 was considered statistically significant.

02

Conditions studied

  • Hip Fractures
  • Acute Pain
  • Emergency Department

Keywords

  • Pericapsular Nerve Group Block (PENG Block)
03

In context

Hip Fractures

848 studies on the registry are indexed under Hip Fractures; 160 are open to participants now.

This study's enrollment of 65 is below the median of 90 across 540 interventional studies indexed under Hip Fractures.

Browse Hip Fractures studies →

Lead sponsor

Dalin Tzu Chi General Hospital is the lead sponsor of 37 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged >20 years presenting to the ED with a diagnosis of traumatic hip fracture during the study timeframe.

Exclusion criteria

Exclusion Criteria:

  • are aged \<20 years
  • coagulopathy
  • injection site infection
  • allergy to opioids or local anesthetics
  • initial pulse oximetry measures of oxygen saturation \<92%
  • initial systolic blood pressure \< 90 mmHg
  • chronic opioid use
  • non-communicative
  • major trauma
  • fractures happened > 24 hours
  • request conservative(non-operative) treatments.
  • The investigators also exclude patients if the NB providers are unavailable.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Ultrasound-guided Pericapsular Nerve Group (PENG) Block

    PENG blocks is performed by Emergency Medicine board-certified emergency physicians (EPs) with standard training program. PENG block is performed using a spinal needle (NIPRO® 21G × 70 mm) at the level of of anterior superior iliac spine, parallel to the inguinal crease, with real-time ultrasound guidance, according to the steps published by Girón-Arango et al in 2018. The investigators use 20 ml of 1% lidocaine for nerve block because this drug has a short onset time, which is adequate to relieve pain before surgical intervention.

    Procedure: Ultrasound-guided Pericapsular Nerve Group (PENG) Block

  • Active comparator
    Intravenous Morphine

    Dosage of intravenous morphine was determined according to 0.1 mg per kg; EPs were instructed to aim to reduce the pain by 50% or per patient request.

    Procedure: Ultrasound-guided Pericapsular Nerve Group (PENG) Block

Interventions

  • ProcedureUltrasound-guided Pericapsular Nerve Group (PENG) Block

    PENG blocks is performed by Emergency Medicine board-certified emergency physicians (EPs) with standard training program. PENG block is performed using a spinal needle (NIPRO® 21G × 70 mm) at the level of of anterior superior iliac spine, parallel to the inguinal crease, with real-time ultrasound guidance, according to the steps published by Girón-Arango et al in 2018. The investigators use 20 ml of 1% lidocaine for nerve block because this drug has a short onset time, which is adequate to relieve pain before surgical intervention.

06

What researchers measure

Primary outcomes

  1. Pain intensity difference (PID)

    Pain intensity was investigated at rest and with movement using the 11-point numeric rating-scale (NRS) from 0 (no pain) to 10 (worst pain), and pain-intensity difference(PID) represents the difference in NRS scores between any observation time and the baseline.

    Time frame: 24 hours

Secondary outcomes

  1. postdose quadriceps strength

    Quadriceps strength was assessed using the knee extension test by using Oxford muscle strength scale(from grade 0(no muscle movement) to grade 5(normal strength)) .

    Time frame: 24 hours

  2. Rescue opioid consumption

    measured in morphine milligram equivalents (MME)

    Time frame: 24 hours

  3. Incidence of nerve block complications

    Any complications or side effects of nerve blocks including local infection, intravascular injection of local anesthetics and immediate systemic toxicity.

    Time frame: 24 hours

  4. Incidence of opioid side effects

    Any side effects of opioids such as drowsiness, desaturation, nausea and vomiting, delirium, or respiratory distress.

    Time frame: 24 hours

  5. Patient-reported outcome

    patients were asked whether they would choose the same anesthetic handling; "yes" or "no"

    Time frame: 24 hours

07

Study locations

1 site
  • Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
    Chiayi City, 622, Taiwan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04997785
Lead sponsor
Dalin Tzu Chi General Hospital
Responsible party
TSAI TOU YUAN (Emergency department physician, Principal Investigator, Dalin Tzu Chi General Hospital) — Principal investigator
First posted
Aug 10, 2021
Start date
Aug 30, 2021
Primary completion
May 8, 2022
Completion
May 8, 2022
Last update
Jan 18, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion